These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


150 related items for PubMed ID: 7529840

  • 1. [Type III procollagen N-terminal peptide and type IV collagen-7S level in the serum and BALF of patients with non-Hodgkin's lymphoma before and after chemotherapy].
    Niitsu N, Umeda M.
    Rinsho Ketsueki; 1994 Nov; 35(11):1267-75. PubMed ID: 7529840
    [Abstract] [Full Text] [Related]

  • 2. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.
    Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, Beshevkin M, Silver RT, Reisman AM, Pasmantier MW.
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):23-33. PubMed ID: 2456620
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 10. [The COP-BLAM III therapy of non-Hodgkin's lymphoma].
    Arai N, Hara A, Umeda M, Shirai T.
    Rinsho Ketsueki; 1991 Nov 01; 32(11):1447-52. PubMed ID: 1721937
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].
    Gerhartz HH, Thiel E, Hiller E, Nerl C, Wilmanns W, Huhn D.
    Dtsch Med Wochenschr; 1986 Oct 03; 111(40):1511-5. PubMed ID: 2428572
    [Abstract] [Full Text] [Related]

  • 12. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW, McGuire BW, Cruickshank SE, Johnson DH.
    Oncologist; 2005 Feb 03; 10(2):138-49. PubMed ID: 15709216
    [Abstract] [Full Text] [Related]

  • 13. [Serum type III procollagen peptide in diagnosis of lung fibrosis due to silicosis and bleomycin toxicity].
    Okuno F, Maruyama K, Okazaki I, Arai M, Suzuki H.
    J UOEH; 1986 Mar 20; 8 Suppl():355-61. PubMed ID: 2425407
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis C.
    Abe S, Narita R, Hiura M, Jia DM, Tabaru A, Otsuki M.
    J Gastroenterol; 2004 Mar 20; 39(3):247-54. PubMed ID: 15065002
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.